RTI Biologics Schedules 2013 First Quarter Earnings and Conference Call for
April 25, 2013
ALACHUA, Fla. -- April 18, 2013
RTI Biologics Inc. (RTI) (Nasdaq:RTIX), a leading provider of orthopedic and
other biologic implants, announced today that it plans to release financial
results from the first quarter 2013 on Thursday, April 25, 2013 prior to the
RTI will host a conference call and simultaneous audio webcast to discuss
first quarter 2013 results at 8:30 a.m. ET the same day. The conference call
can be accessed by dialing (877) 383-7419 (U.S.) or (760) 666-3754
(International). The webcast can be accessed through the investor section of
RTI’s website at www.rtix.com. A replay of the conference call will be
available on RTI’s website for one month following the call.
About RTI Biologics Inc.
RTI Biologics Inc. is a leading provider of sterile biologic implants for
surgeries around the world with a commitment to advancing science, safety and
innovation. RTI prepares human donated tissue and animal tissue for
transplantation through extensive testing and screening, precision shaping and
using proprietary, validated processes. These allograft and xenograft implants
are used in orthopedic, dental and other specialty surgeries.
RTI’s innovations continuously raise the bar of science and safety for
biologics – from being the first company to offer precision-tooled bone
implants and assembled technology to maximize each gift of donation, to
inventing validated sterilization processes that include viral inactivation
steps. These processes — BioCleanse®, Tutoplast® and Cancelle® SP DBM — have a
combined record of more than four million implants distributed with zero
incidence of implant-associated infection. These processes have been validated
by tissue type to inactivate or remove viruses, bacteria, fungi and spores
from the tissue while maintaining biocompatibility and functionality.
RTI’s worldwide corporate headquarters are located in Alachua, Fla., with
international locations in Germany and France. The company is accredited by
the American Association of Tissue Banks in the United States and is a member
RTI Biologics Inc.
Chief Financial Officer
Jenny Highlander, APR, 386-418-8888
Press spacebar to pause and continue. Press esc to stop.